The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Rising Dose Study of AR882, a Potent Uricosuric Agent, in Healthy Adult Male Volunteers

A randomized, double-blind, placebo-controlled, single ascending dose study of AR882 in healthy adult males.

Inclusion Criteria:

• Serum uric acid level ≥ 4.5 mg/dL (268 µmol/L)
• Body weight no less than 50 kg and body mass index (BMI) within the range of ≥18 and ≤33 kg/m2
• Must be free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations or procedures

Exclusion Criteria:

• Malignancy within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin
• History of cardiac abnormalities
• History and/or presence of drug addiction or excessive use of alcohol